Collegium Pharmaceutical (COLL) Competitors $39.59 +0.43 (+1.10%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$39.58 -0.01 (-0.01%) As of 09/3/2025 06:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock COLL vs. CRSP, TGTX, ACAD, KRYS, CYTK, MENS, ADMA, PCVX, AAPG, and PTCTShould you be buying Collegium Pharmaceutical stock or one of its competitors? The main competitors of Collegium Pharmaceutical include CRISPR Therapeutics (CRSP), TG Therapeutics (TGTX), ACADIA Pharmaceuticals (ACAD), Krystal Biotech (KRYS), Cytokinetics (CYTK), Jyong Biotech (MENS), ADMA Biologics (ADMA), Vaxcyte (PCVX), Ascentage Pharma Group International (AAPG), and PTC Therapeutics (PTCT). These companies are all part of the "pharmaceutical products" industry. Collegium Pharmaceutical vs. Its Competitors CRISPR Therapeutics TG Therapeutics ACADIA Pharmaceuticals Krystal Biotech Cytokinetics Jyong Biotech ADMA Biologics Vaxcyte Ascentage Pharma Group International PTC Therapeutics CRISPR Therapeutics (NASDAQ:CRSP) and Collegium Pharmaceutical (NASDAQ:COLL) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends. Which has more volatility & risk, CRSP or COLL? CRISPR Therapeutics has a beta of 1.81, meaning that its stock price is 81% more volatile than the S&P 500. Comparatively, Collegium Pharmaceutical has a beta of 0.63, meaning that its stock price is 37% less volatile than the S&P 500. Which has stronger earnings & valuation, CRSP or COLL? Collegium Pharmaceutical has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCRISPR Therapeutics$37.31M129.15-$366.25M-$5.43-9.76Collegium Pharmaceutical$631.45M1.97$69.19M$1.0438.07 Does the media favor CRSP or COLL? In the previous week, CRISPR Therapeutics had 11 more articles in the media than Collegium Pharmaceutical. MarketBeat recorded 19 mentions for CRISPR Therapeutics and 8 mentions for Collegium Pharmaceutical. CRISPR Therapeutics' average media sentiment score of 1.11 beat Collegium Pharmaceutical's score of 0.70 indicating that CRISPR Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CRISPR Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Collegium Pharmaceutical 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Is CRSP or COLL more profitable? Collegium Pharmaceutical has a net margin of 5.13% compared to CRISPR Therapeutics' net margin of -1,229.43%. Collegium Pharmaceutical's return on equity of 97.28% beat CRISPR Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets CRISPR Therapeutics-1,229.43% -20.05% -17.09% Collegium Pharmaceutical 5.13%97.28%13.87% Do institutionals & insiders have more ownership in CRSP or COLL? 69.2% of CRISPR Therapeutics shares are owned by institutional investors. 4.1% of CRISPR Therapeutics shares are owned by company insiders. Comparatively, 2.5% of Collegium Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Do analysts prefer CRSP or COLL? CRISPR Therapeutics presently has a consensus target price of $71.60, suggesting a potential upside of 35.15%. Collegium Pharmaceutical has a consensus target price of $42.33, suggesting a potential upside of 6.93%. Given CRISPR Therapeutics' higher probable upside, research analysts plainly believe CRISPR Therapeutics is more favorable than Collegium Pharmaceutical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CRISPR Therapeutics 1 Sell rating(s) 7 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.47Collegium Pharmaceutical 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.00 SummaryCollegium Pharmaceutical beats CRISPR Therapeutics on 9 of the 17 factors compared between the two stocks. Get Collegium Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for COLL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding COLL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart COLL vs. The Competition Export to ExcelMetricCollegium PharmaceuticalMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.22B$2.51B$5.77B$9.77BDividend YieldN/A48.51%6.66%4.49%P/E Ratio38.0722.6482.3726.60Price / Sales1.97714.67536.82175.38Price / Cash3.1426.3325.7028.92Price / Book5.376.7910.646.56Net Income$69.19M$32.94M$3.28B$266.04M7 Day Performance2.06%0.75%-0.08%-0.58%1 Month Performance31.66%8.36%10.36%6.24%1 Year Performance5.80%0.53%49.00%22.21% Collegium Pharmaceutical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)COLLCollegium Pharmaceutical2.9952 of 5 stars$39.59+1.1%$42.33+6.9%+5.8%$1.22B$631.45M38.07210Insider TradeCRSPCRISPR Therapeutics3.5926 of 5 stars$51.83-2.3%$71.60+38.1%+16.4%$4.71B$37.31M-9.55460Analyst RevisionTGTXTG Therapeutics4.4119 of 5 stars$29.33+1.3%$46.25+57.7%+40.2%$4.65B$329M79.27290News CoveragePositive NewsGap UpACADACADIA Pharmaceuticals4.0432 of 5 stars$25.99-0.9%$28.88+11.1%+57.2%$4.38B$957.80M19.54510Analyst RevisionKRYSKrystal Biotech4.8124 of 5 stars$147.70-2.0%$210.38+42.4%-19.6%$4.27B$290.52M30.02210Positive NewsCYTKCytokinetics4.1069 of 5 stars$35.33-5.4%$71.58+102.6%-8.4%$4.23B$18.47M-6.93250Trending NewsAnalyst ForecastInsider TradeOptions VolumeMENSJyong BiotechN/A$54.81-1.3%N/AN/A$4.17BN/A0.0031News CoverageADMAADMA Biologics3.9097 of 5 stars$17.26-0.7%$27.67+60.3%+2.0%$4.12B$426.45M20.07530Positive NewsPCVXVaxcyte2.7844 of 5 stars$30.79+0.1%$136.50+343.3%-70.9%$4.00BN/A-7.49160News CoveragePositive NewsAAPGAscentage Pharma Group InternationalN/A$42.47+3.3%N/AN/A$3.95B$134.35M0.00600Positive NewsPTCTPTC Therapeutics3.8467 of 5 stars$49.33-0.9%$69.15+40.2%+66.3%$3.92B$806.78M7.081,410News CoveragePositive NewsAnalyst Forecast Related Companies and Tools Related Companies CRSP Competitors TGTX Competitors ACAD Competitors KRYS Competitors CYTK Competitors MENS Competitors ADMA Competitors PCVX Competitors AAPG Competitors PTCT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:COLL) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredFree: The Crypto Summit That Could Change Your Life27 industry leaders share urgent market intel (free access)... For a very limited time, you can claim your ...Crypto 101 Media | SponsoredThis Massive Market is Ripe for Disruption by this NasdaqFanatics Hit $31B. This Nasdaq Company Is Building the Next Wave Fanatics built a merch empire by owning th...i2i Marketing Group, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Collegium Pharmaceutical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Collegium Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free COLL Stock Alerts